Pharmesis International Ltd.
5 Kallang Sector
#03-02
Singapore 349279
Company registration no.: 200309641E

PROFIT GUIDANCE FOR UNAUDITED FINANCIAL RESULTS FOR SECOND QUARTER ENDED 30 JUNE 2016

The Board of Directors (the "**Board**") of Pharmesis International Ltd. (the "**Company**") wishes to announce that after preliminary assessment of the Company's unaudited financial results for the second quarter ended 30 June 2016 ("**2Q2016**"), the Board would like to inform the shareholders and investors that the Company is expected to report a net loss for unaudited financial results for 2Q2016.

The expected net loss was mainly attributed to lower revenue from prescribed drug segment.

Further details of the Company's financial performance will be disclosed when the Company announces its unaudited financial results for 2Q2016 on 12 August 2016.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Jiang Yun
Executive Director and Chief Executive Officer
5 August 2016